QIAamp Viral RNA Mini Kit
英文名称: QIAamp Viral RNA Mini Kit
型号:null    产品货号: 52904
价格:请致电:010-57128832,18610462672
品牌: qiagen
试剂级别: 分子生物学级

规格:Mini spin columns
样品来源:血清、血浆、尿液、脑脊液和其他无细胞体液,细胞培养上清液
样品量:140 µl
制备时间:20-40 分钟
常规产量:任何RNA病毒滴定,>90%回收率
洗脱体积:50 µl

QIAamp Viral RNA Mini Kit 可从无细胞液体中纯化病毒核酸。可用该试剂盒纯化的病毒核酸包括,hepatitis A、C和D-G病毒,HIV,BVDV以及肠道病毒中分离RNA等。

原理

QIAamp Viral RNA Mini Kit 应用快速离心柱或真空过程简化了从无细胞体液中分离病毒RNA的步骤。病毒RNA特异性地结合到QIAamp硅胶膜上,而污染物则流过该膜。通过两次高效洗涤完全去除诸如二价阳离子和蛋白质等PCR抑制子,然后应用水或试剂盒提供的缓冲夜洗脱高纯度的病毒。

QIAamp RNA技术从无细胞体液中抽提病毒RNA,可直接用于RT-PCR和印记分析。QIAamp样品制备技术已完全注册,应用该技术纯化的核酸可用于所有分子分析和其他下游应用, 不会引起专利侵权。*

流程

经优化的缓冲夜和酶裂解样品,稳定核酸,同时促进RNA选择性地结合到QIAamp膜上。为确保RNA的完整性,在高度的变性条件裂解样品,使RNase失活。加入酒精并将裂解液装入QIAamp离心柱。洗涤缓冲夜用于去除杂质,然后用水或低盐缓冲夜洗脱RNA。

真空处理

为更快、更方便地纯化RNA,可用真空方式替代离心处理样品。QIAamp Mini 离心柱通过VacValves和VacConnectors(QIAamp Vac Accessory Set中提供)与真空底座QIAvac 24 manifold相连。当样品流速明显不均匀的情况下使用VacValves,以保持真空状态。一次性VacConnectors则用于避免交叉污染。使用VacConnectors也支持QIAamp 纯化过程在配备有适配器QIAvac Luer AdaptersQIAvac 6S上运行。

下游应用

回收率高达99%,支持应用巢式RT-PCR 检测100拷贝以下的病毒RNA(见图"Amplification of RNA from Plasma")。表格"Example of Viral RNA Recovery" 显示,QIAamp Viral RNA Mini Kit 可以 100% 检测速度检测100-拷贝/ml 样品中的HCV RNA。

从细胞中纯化病毒DNA应当使用QIAamp DNA Blood KitsQIAamp DNA Mini Kit;从细胞中纯化病毒RNA可选择 QIAamp RNA Blood Mini Kit 或合适的RNeasy Kit。也可参考QIAamp Selection Guide

Example of Viral RNA Recovery

IU/mlHCV geq/mlPositives
(spin protocol)
Positives
(vacuum protocol)

123333100%100%
37100100%100%
12.33361%64%
7.420-59%
3.71048%-

The QIAamp Viral RNA Mini Kit was used to isolate RNA from serum. HCV RNA was then amplified and detected using the Roche AMPLICOR HCV v2.0 Kit. These data were accepted by the German regulatory authority Paul Ehrlich Institute for validation of QIAamp Viral RNA Kits for sample preparation in HCV RNA screening of donated blood. Complete validation includes determination of sensitivity, precision, reproducibility, and robustness.
The QIAamp Viral RNA Mini Kit is not approved for clinical use in blood banks in the United States of America. The analytical data shown above have been used to support the use of the product in processing donor blood for HCV screening in Germany only. These validation data are based on the German PEI announcement from 25.02.1998 regarding results of the stepwise procedure to reduce the risk of hepatitis B, hepatitis C, and HIV infection by recipients of erythrocyte concentrates and the PEI announcement from 5.6.1998 about reducing the risk of hepatitis C virus contamination in thrombocyte concentrates.

d> Times New Roman; FONT-SIZE: 9pt; mso-font-kerning: 1.0pt; mso-fareast-font-family: 宋体; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA" lang=EN-US>10nmol

650

询价

Customer - defined miRNA inhibitor

10nmol

650

询价